Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism

Targeting Bruton's tyrosine kinase (BTK) with the small molecule BTK inhibitor ibrutinib has significantly improved patient outcomes in several B-cell malignancies, with minimal toxicity. Given the reported expression and constitutive activation of BTK in acute myeloid leukemia (AML) cells, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotin, Lianne E., Gronda, Marcela, MacLean, Neil, Hurren, Rose, Wang, XiaoMing, Lin, Feng-Hsu, Wrana, Jeff, Datti, Alessandro, Barber, Dwayne L., Minden, Mark D., Slassi, Malik, Schimmer, Aaron D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823070/
https://www.ncbi.nlm.nih.gov/pubmed/26624983
http://dx.doi.org/10.18632/oncotarget.6409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823070/
https://www.ncbi.nlm.nih.gov/pubmed/26624983
http://dx.doi.org/10.18632/oncotarget.6409

Ejemplares similares